ÂÜÀòÂÒÂ×

Mark Jackson is the Chief Operating Officer and Co-Founder of AdvantiGen Biosciences, a company focused on deep tissue imaging using patented fluorophore technology. Mark is also the Chief Executive Officer of IMMUN-IP, which specializes in immunological platform technology. Mark has previously worked as a Consultant for Madeleine Pharmaceuticals and NovoRep, and as a Scientist for NeoClone. Prior to their corporate roles, Mark was a Research Specialist at the University of Wisconsin-Madison. Mark holds a BS in Molecular Biology from the University of Wisconsin-Madison and completed coursework in Chemistry-Chemical Engineering at Technische Universität Berlin.